首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
目的探讨门诊式森田疗法与住院式森田疗法辅助治疗抑郁症的疗效的差异。方法选择来院就诊的抑郁症患者60例,随机分成门诊森田疗法组和住院森田疗法组各30例。门诊森田疗法组接受药物治疗联合门诊式森田疗法,而住院森田疗法组接受药物治疗联合住院式森田疗法,观察8周,再随访3个月。在治疗前、治疗8周末及随访3个月时分别对两组患者实施汉密尔顿抑郁量表(HAMD)和健康状况调查问卷(SF-36)来评价患者的抑郁状态和生活质量。结果①治疗8周末及随访3个月时,两组的汉密尔顿量表得分差异均无统计学意义(t=0.02~1.33,P0.05);②在健康状况调查问卷中,治疗8周末,门诊森田疗法组患者的社会功能(SF)得分低于住院森田疗法组患者,差异有统计学意义(t=2.19,P0.05);随访3个月时,门诊森田疗法组患者的躯体疼痛(BP)和精神健康(MH)两个维度的得分低于住院森田疗法组患者,差异有统计学意义(t=2.34,2.41,P0.05)。结论门诊式森田疗法与住院式森田疗法相比,在减轻患者抑郁症状的疗效方面无差异,在改善生活质量的疗效方面有差异性,住院式森田疗法优于门诊式森田疗法。  相似文献   

2.
目的探讨门诊森田疗法辅助药物治疗失眠症的近期疗效和远期疗效。方法将60例失眠症患者随机分为研究组和对照组各30例,两组患者均口服佐匹克隆治疗,研究组辅以门诊森田疗法,于治疗前、治疗4周后及随访3个月时,分别用匹兹堡睡眠质量指数(PSQI)评定近期和远期临床效果。结果治疗4周后,研究组PSQI中6个因子分低于对照组,差异有统计学意义(t=1.98~2.76,P0.05);随访3个月时,PSQI中6个因子分低于对照组,差异有统计学意义(t=2.35~4.09,P0.05)。结论门诊森田疗法辅助药物治疗失眠症的近期效果和远期效果均优于单纯药物治疗。  相似文献   

3.
目的评价文拉法辛配合认知行为疗法对抑郁症的疗效。方法将64例抑郁症患者随机分为两组,研究组采用文拉法辛合并认知行为治疗,对照组仅用文拉法辛治疗,两组作8周持续治疗观察,于入组前及入组后第4,8周末分别用汉密尔顿抑郁量表(HAMD),汉密尔顿焦虑量表(HAMA)进行评定。结果①治疗前研究组和对照组HAMD、HAMA评分差异无统计学意义。第4周末研究组HAMD评分低于对照组(t=3.081,P<0.05),直至第8周末两组HAMD评分仍有差异(t=4.077,P<0.05);②第4周末研究组HAMA评分低于对照组(t=3.083,P<0.05),直至第8周末两组HAMA评分仍有差异(t=4.079,P<0.05)。结论文拉法辛配合认知行为疗法对抑郁症有效,并且远期疗效好。  相似文献   

4.
目的探讨药物合并认知行为治疗对抑郁症患者的疗效及生活质量的影响。方法将72例抑郁症患者随机分为药物合并认知行为治疗组与药物治疗组,治疗观察8周。于治疗前及治疗2、4、8周末采用汉密尔顿抑郁量表(HAM D-24)、临床疗效总评量表(CG I)与副反应量表(TESS)分别评定疗效与不良反应。于治疗前及治疗8周末采用生活质量综合评定问卷(GQOL-74)评定患者生活质量。结果①治疗8周末两组HAM D评分有显著性差异(t=5.12,P<0.01);②两组G I评分治疗6、8周末组间比较有显著性差异(t=2.22,2.65;P<0.05),E I评分治疗8周末组间比较有显著性差异(t=1.95,P<0.05);③研究组治疗8周末除物质生活维度外,其他3个维度评分与对照组比较均有显著性差异(t=2.24,3.34,2.46;P<0.05)。结论药物合并认知行为治疗可提高抑郁症的治疗效果和生活质量。  相似文献   

5.
目的探讨帕罗西汀联合认知疗法治疗抑郁症的临床疗效。方法将90例抑郁症患者随机分为研究组与对照组各45例,两组均口服帕罗西汀治疗,研究组在此基础上联合认知心理治疗。观察8周。于治疗前及治疗第2、4、8周末采用汉密尔顿抑郁量表(HAM D)及副反应量表(TESS)评定临床疗效和不良反应。出院后随访1年,统计复发率。结果治疗8周末,研究组有效率95.6%,对照组为82.2%,两组比较差异有显著性(χ2=4.05,P0.05)。治疗2周末起,两组汉密尔顿抑郁量表总分均较治疗前有显著下降(t=9.627和6.439,P0.01),研究组治疗2周末起较对照组下降更显著(t=1.766,P0.05)。随访1年末研究组复发率15.5%,对照组为33.3%,研究组复发率显著低于对照组(χ2=3.85,P0.05)。结论帕罗西汀联合认知心理治疗能显著提高抑郁症的临床疗效,有效预防复发,改善预后。  相似文献   

6.
目的探讨综合干预对门诊抑郁症患者的疗效,为抑郁症的防治研究提供临床依据。方法方便抽样法选取2012年3月1日-2013年2月31日来某疗养院门诊就诊的抑郁症患者144例为研究对象,随机分成研究组和对照组各72例,研究组接受中医药治疗联合综合干预,对照组只接受单独的中医药治疗,观察8周。在治疗前、治疗4、8周末分别对两组患者进行汉密尔顿抑郁量表(HAMD)和症状自评量表(SCL-90)自评。结果①两组干预4周末和8周末HAMD总分较干预前均显著下降,研究组下降更明显(P0.01),显著低于对照组(P0.01)。根据减分率评定疗效,干预8周末研究组治愈显效率比对照组更高(χ2=6.95,P0.01);②干预4周末,研究组与对照组相比强迫、人际敏感、抑郁、敌对和均分均有显著下降(t=5.485,3.972,3.296,2.707,3.111;P0.01),干预8周末两组相比全部因子分均有显著下降(t=3.655,9.110,6.452,4.896,3.575,3.147,3.325,2.915,4.027,6.959;P0.01)。结论综合干预能有效提高门诊抑郁症患者的疗效,有效改善抑郁症患者的心理健康状况,促进患者康复。  相似文献   

7.
改良森田疗法治疗抑郁症对照观察   总被引:1,自引:0,他引:1  
目的探讨改良森田疗法合并药物治疗抑郁症的疗效与安全。方法对106例抑郁症患者随机分为2组,改良森田疗法合并药物组52例,氟西汀组54例,疗程8周,用汉密尔顿抑郁量表(HAMD)[1]、副反应量表(TESS)评定疗效和不良反应。结果治疗8周后改良森田疗法合并药物治疗抑郁症组汉密尔顿抑郁量表评分显著低于氟西汀组(t=-4.443,P〈0.01);改良森田疗法合并药物治疗组主要不良副反应明显低于氟西汀组(χ2=13.07,P〈0.01)。结论改良森田疗法合并药物治疗是一种安全、有效的抗抑郁治疗方法。  相似文献   

8.
目的探讨生物反馈辅助治疗抑郁症的疗效。方法对符合CCMD-抑郁症诊断标准的60例患者,随机分为研究组和对照组,研究组在对照组基础上辅以多参数生物反馈治疗。采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)分别观察疗效,连续观察8周。结果在治疗第1周,两组HAMD和HAMA评分均下降,但两组间有显著性差异(t=4.64,4.35;P<0.05)。第2周末开始两组间HAMD和HAMA评分差异无显著性。第8周末两组显效率分别为93.3%和86.7%,差异无统计学意义。结论生物反馈辅助治疗抑郁症起效更快,病人的满意度和依从性更好。  相似文献   

9.
目的比较奥氮平合用氟西汀与单用氟西汀治疗难治性抑郁症的疗效和安全性。方法 72例难治性抑郁患者随机分为两组,研究组给予奥氮平合用氟西汀治疗,对照组给予氟西汀,疗程8周。采用汉密尔顿抑郁量表(HAMD)和治疗中出现的副反应量表(TESS)评定疗效及不良反应。结果治疗8周末两组HAMD评分均显著下降(t=6.712,7.491,P<0.01),研究组显效率高于对照组(t=5.007,P<0.05),两组不良反应均较轻微。结论奥氮平与氟西汀合用比单用氟西汀治疗难治性抑郁症疗效好,不良反应轻微。  相似文献   

10.
目的 探讨被动式音乐治疗辅助治疗抑郁症的疗效.方法 将90例抑郁症患者随机分为研究组和对照组,研究组在对照组基础上辅以被动式音乐治疗.采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)分别观察疗效,连续观察8周.结果 在治疗第1周,两组HAMD和HAMA评分均下降,但两组间有显著性差异(t=4.39,6.43;P<0.05).第2周末开始两组间HAMD和HAMA评分差异无显著性.第8周末两组显效率分别为93.3%和86.7%,差异无统计学意义.结论 被动式音乐治疗辅助治疗抑郁症起效快.  相似文献   

11.
Background: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental. Objective: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma. Methods: This was a randomized, double-blind, parallel-group trial. Three hundred sixty-two patients 12 years of age or older were treated with study drug administered by means of nebulization 3 times daily for 28 days. The primary endpoint was peak change in FEV1 after 4 weeks. Results: The change in peak FEV1 response to the first dose in the combined levalbuterol group was significantly greater compared with the combined racemic albuterol group (0.92 and 0.82 L, respectively; P = .03), with similar but nonsignificant results after 4 weeks (0.84 and 0.74 L, respectively). Improvement in FEV1 was similar for levalbuterol 0.63 mg and racemic albuterol 2.5 mg and greatest for levalbuterol 1.25 mg. Racemic albuterol 1.25 mg demonstrated the weakest bronchodilator effect, particularly after chronic dosing. The greatest increase in FEV1 was seen after levalbuterol 1.25 mg, especially in subjects with severe asthma. All active treatments were well tolerated, and β-adrenergic side effects after administration of levalbuterol 0.63 mg were reduced relative to levalbuterol 1.25 mg or racemic albuterol 2.5 mg. At week 4, the predose FEV1 value was greatest in patients who received levalbuterol or placebo when compared with those who received racemic albuterol. The difference was more evident and was statistically significant in patients who were not receiving inhaled corticosteroids. Conclusion: Levalbuterol appears to provide a better therapeutic index than the standard dose of racemic albuterol. These results support the concept that (S)-albuterol may have detrimental effects on pulmonary function. (J Allergy Clin Immunol 1998;102:943-52.)  相似文献   

12.
13.
Background: The use of rituximab (RTX) is increasing, even in developing countries. It has become the first-line therapy or adjuvant to chemotherapy (CHOP; cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) for various diseases, including B cell lymphoma and autoimmune diseases.

Aim: We describe the infectious diseases and immunological markers associated with RTX treatment of patients with non-Hodgkin lymphoma (NHL).

Methods: Serum immunoglobulins were determined before and after intravenous immunoglobulin (IVIg) administration. Pneumo-23IgG-specific anti-pneumococcal antibodies were evaluated before and after vaccination. Immunophenotyping and lymphocyte proliferation were determined in the course of the treatment.

Results: Seven patients were followed and median age was 56.0?±?5.0?years (range, 41.9–71.6?years). At baseline, the mean level of IgG was 333.7?±?40.8?and IgM 40.9?±?11.3?mg/dL, respectively; immunoglobulin A and E (IgA and IgE) were under the limit of detection. Two patients had reduced or absent B cells and T cell subsets were at normal levels in five patients. All patients failed to mount an efficient post-vaccination immune response against hepatitis B virus, tetanus, diphtheria and against the 23-valent pneumococcal polysaccharide vaccine. During RTX/CHOP treatment, human-IgG-immunoglobulin (IVIg) therapy was introduced in six patients after recurrent infections, including community-acquired pneumonia (85.7%), chronic sinusitis (85.7%) and gastroenteritis (42.9%).

Conclusion: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections.  相似文献   

14.
Abstract

The incidence of self-mutilation and suicidality among patients with dissociative disorders is quite high. It is necessary for clinicians working with this population to be adept at dealing with safety problems. This article presents a sequence of basic steps that can be used when helping dissociative patients establish safety, a discussion of the functions of self-destructiveness, and an overview of specific experiences and thinking patterns that contribute to self-destructiveness among dissociative patients.  相似文献   

15.
16.
目的 观察拉米夫定与泛昔洛韦联合治疗乙型肝炎病毒(HBV)慢性感染的临床疗效。方法 慢性乙型肝炎患者90例。设联合治疗组28例,单用拉米夫定组30例,单用泛昔洛韦组32例。联合治疗组给予口服拉米夫定0.1g/d(PO),泛昔洛韦1.5g/d(PO),24周。拉米夫定、泛昔洛韦单用组剂量及疗程分别同联合治疗组。结果 3组均无明显副反应,丙氨酸转氨酶(ALT)复常率无差异。3组HBV DNA阴转率分别为89.3%、66.7%、40.6%,差异有显著性。乙型肝炎表面抗原(HBeAg)阴转率分别为28.6%、23.3%、21.9%,差异无显著性。结论 拉米夫定与泛昔洛韦联合用药安全、耐受性好,临床显示联合治疗对HBV DNA的抑制作用显著优于单用药。  相似文献   

17.
18.
Atopy in children with otitis media with effusion   总被引:1,自引:0,他引:1  
  相似文献   

19.
Intervention with epinephrine in hypotension associated with mastocytosis   总被引:1,自引:0,他引:1  
The occurrence of the episodes of vasodilatory hypotension can be a life-threatening manifestation of systemic mastocytosis. This article describes the reversal by epinephrine of episodes of severe hypotension in two hospitalized patients with mastocytosis. Recognition of the efficacy of epinephrine in hypotension associated with mastocytosis can be important when other methods fail to restore hemodynamic stability.  相似文献   

20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号